Notice Information
Notice Title
SMA Newborn Screening Kits
Notice Description
The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).
Lot Information
Lot 1
The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). Scotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel. SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2. SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.
Procurement Information
In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-r6ebe6-0000826401
- Publication Source
- Public Contracts Scotland
- Latest Notice
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- OJEU - F3 - Contract Award Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Limited
- Procurement Method Details
- Award procedure without prior publication of a call for competition
- Tender Suitability
- Not specified
- Awardee Scale
- SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33696500 - Laboratory reagents
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £237,847 £100K-£500K
Notice Dates
- Publication Date
- 2 Apr 20262 days ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 5 Mar 20261 months ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Complete
- Awards Status
- Not Specified
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS GREATER GLASGOW AND CLYDE
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- GLASGOW
- Postcode
- G4 0SF
- Post Town
- Glasgow
- Country
- Scotland
-
- Major Region (ITL 1)
- TLM Scotland
- Basic Region (ITL 2)
- TLM3 West Central Scotland
- Small Region (ITL 3)
- TLM32 Glasgow City
- Delivery Location
- TLM82 Glasgow City
-
- Local Authority
- Glasgow City
- Electoral Ward
- Dennistoun
- Westminster Constituency
- Glasgow North East
Further Information
Notice Documents
-
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048
SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). -
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-r6ebe6-0000826401-2026-04-02T00:00:00Z",
"date": "2026-04-02T00:00:00Z",
"ocid": "ocds-r6ebe6-0000826401",
"initiationType": "tender",
"parties": [
{
"id": "org-43",
"name": "NHS Greater Glasgow and Clyde",
"identifier": {
"legalName": "NHS Greater Glasgow and Clyde"
},
"address": {
"streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street",
"locality": "Glasgow",
"region": "UKM82",
"postalCode": "G4 0SF"
},
"contactPoint": {
"email": "william.cullen@nhs.scot",
"telephone": "+44 1412015388",
"url": "http://"
},
"roles": [
"buyer"
],
"details": {
"classifications": [
{
"id": "Body governed by public law",
"scheme": "TED_CA_TYPE"
},
{
"id": "07",
"description": "Health",
"scheme": "COFOG"
}
],
"url": "http://www.nhsggc.scot/about-us/procurement/"
}
},
{
"id": "org-44",
"name": "Labsystems Diagnostics OY",
"identifier": {
"legalName": "Labsystems Diagnostics OY"
},
"address": {
"streetAddress": "Tiilitie 3, Finlandia",
"locality": "Vantaa",
"region": "FI1B",
"postalCode": "01720"
},
"contactPoint": {
"email": "sales@ladsystemsdx.com",
"telephone": "+44 358201557530"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme",
"url": "http://"
}
},
{
"id": "org-45",
"name": "Glasgow Sheriff Court",
"identifier": {
"legalName": "Glasgow Sheriff Court"
},
"address": {
"streetAddress": "PO Box 23, 1 Carlton Place",
"locality": "Glasgow",
"postalCode": "G5 9DA"
},
"contactPoint": {
"url": "http://"
},
"roles": [
"reviewBody"
]
},
{
"id": "org-19",
"name": "NHS Greater Glasgow and Clyde",
"identifier": {
"legalName": "NHS Greater Glasgow and Clyde"
},
"address": {
"streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street",
"locality": "Glasgow",
"region": "UKM82",
"postalCode": "G4 0SF"
},
"contactPoint": {
"email": "william.cullen@nhs.scot",
"telephone": "+44 1412015388",
"url": "http://"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"classifications": [
{
"id": "Body governed by public law",
"scheme": "TED_CA_TYPE"
},
{
"id": "07",
"description": "Health",
"scheme": "COFOG"
}
],
"url": "http://www.nhsggc.scot/about-us/procurement/"
}
},
{
"id": "org-20",
"name": "Labsystems Diagnostics OY",
"identifier": {
"legalName": "Labsystems Diagnostics OY"
},
"address": {
"streetAddress": "Tiilitie 3, Finlandia",
"locality": "Vantaa",
"region": "FI1B",
"postalCode": "01720"
},
"contactPoint": {
"email": "sales@ladsystemsdx.com",
"telephone": "+44 358201557530"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme",
"url": "http://"
}
},
{
"id": "org-21",
"name": "Glasgow Sheriff Court",
"identifier": {
"legalName": "Glasgow Sheriff Court"
},
"address": {
"streetAddress": "PO Box 23, 1 Carlton Place",
"locality": "Glasgow",
"postalCode": "G5 9DA"
},
"contactPoint": {
"url": "http://"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"name": "NHS Greater Glasgow and Clyde",
"id": "org-19"
},
"tender": {
"id": "ocds-r6ebe6-0000826401",
"title": "SMA Newborn Screening Kits",
"description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
"status": "complete",
"items": [
{
"id": "1",
"additionalClassifications": [
{
"id": "33696500",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKM82"
},
{
"region": "UKM82"
}
],
"relatedLot": "1"
}
],
"procurementMethod": "limited",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"procurementMethodRationale": "In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.",
"mainProcurementCategory": "goods",
"documents": [
{
"id": "MAR552048",
"documentType": "awardNotice",
"title": "SMA Newborn Screening Kits",
"description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
"url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048",
"format": "text/html"
},
{
"id": "APR553217",
"documentType": "awardNotice",
"title": "SMA Newborn Screening Kits",
"description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
"url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217",
"format": "text/html"
}
],
"lots": [
{
"id": "1",
"description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). Scotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel. SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2. SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.",
"status": "complete",
"hasOptions": false,
"awardCriteria": {
"criteria": [
{
"type": "quality",
"name": "Quality",
"description": "99"
},
{
"type": "price",
"description": "1"
}
]
}
}
],
"coveredBy": [
"GPA"
],
"procurementMethodRationaleClassifications": [
{
"id": "D_OUTSIDE_SCOPE",
"description": "The procurement falls outside the scope of application of the directive"
}
],
"classification": {
"id": "33696500",
"scheme": "CPV"
},
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
}
},
"awards": [
{
"id": "ocds-r6ebe6-0000826401-1",
"suppliers": [
{
"id": "org-44",
"name": "Labsystems Diagnostics OY"
},
{
"id": "org-20",
"name": "Labsystems Diagnostics OY"
}
],
"relatedLots": [
"1"
]
}
],
"contracts": [
{
"id": "ocds-r6ebe6-0000826401-1",
"awardID": "ocds-r6ebe6-0000826401-1",
"status": "active",
"value": {
"amount": 237847,
"currency": "GBP"
},
"dateSigned": "2026-03-05T00:00:00Z"
}
],
"language": "EN",
"description": "No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. (SC Ref:828095)",
"links": [
{
"rel": "canonical",
"href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
},
{
"rel": "canonical",
"href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
}
],
"noticetype": "OJEU - F3 - Contract Award Notice",
"relatedProcesses": [
{
"id": "1",
"relationship": [
"planning"
],
"scheme": "EU-OJ",
"identifier": "2026/S 000-025039"
}
],
"bids": {
"statistics": [
{
"id": "36",
"measure": "bids",
"value": 1,
"relatedLot": "1"
},
{
"id": "37",
"measure": "smeBids",
"value": 1,
"relatedLot": "1"
},
{
"id": "38",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "1"
},
{
"id": "39",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "1"
},
{
"id": "40",
"measure": "electronicBids",
"value": 1,
"relatedLot": "1"
}
]
}
}